This website is intended for use by residents of Sweden only

About Isofol

Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

Read more >>

Upcoming Events

  • May 08, 2024 - May 08, 2024
    Interim report January-March 2024
  • August 21, 2024 - August 21, 2024
    Interim report January-June 2024
  • November 12, 2024 - November 12, 2024
    Interim report June-September 2024

Isofol invites to investor meeting on March 19

GOTHENBURG, Sweden, March 1, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites investors and shareholders to an investor meeting to present…

INVESTORS – latest reports and presentations

FOLLOW US

Stay updated on the latest news by
following Isofol on Linkedin.

LinkedIn logotype
Scroll to Top